Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

Fig. 5

IO Score Independence with Various Clinical Factors and Genomic Biomarkers A Series of bivariate Cox proportional hazards with various Clinical Factors. (Note ECOG Status (0, 1, and 2) and Tobacco Use (Never Smokers versus Previous Smokers versus Current Smokers) were treated as increasing risk factors. Metastasis was categorized as lymph node involvement versus either liver or visceral metastasis.); B Series of bivariate Cox proportional hazards with various Genomic Biomarkers. IC1 and IC2/3 is PD-L1 staining in immune cells of  > 1% and  > 5% of cells, respectively. TMB-high and TMB-low refer TMB  ≥ 10 mutations and  < 10 mutations per megabase, respectively. The IO Score maintained its significance in every analysis

Back to article page